What Is Drug Detox? Medical Withdrawal Protocols Explained

Withdrawal onset ranges from 6 hours post-last-drink (alcohol) to 7 days post-last-dose (long-acting benzodiazepines); resolution ranges from 5 days (stimulants) to 8 weeks (benzodiazepines). Each substance class produces a distinct withdrawal syndrome with defined onset, peak, and resolution timeframes. The following are the 4 substance classes and their withdrawal profiles:

• Opioids (heroin, fentanyl, oxycodone) — short-acting opioid withdrawal begins 8–24 hours after last use, peaks at days 1–3, and resolves in 5–10 days. Long-acting opioid withdrawal — methadone — begins 36–48 hours after last use, peaks at 72–96 hours, and resolves over 2–3 weeks. The 5 primary opioid withdrawal symptoms are muscle aches, diarrhea, nausea, insomnia, and dysphoria. Opioid withdrawal is intensely uncomfortable but not directly life-threatening in otherwise healthy adults. See the opioid detox timeline for a day-by-day withdrawal schedule.
• Alcohol — withdrawal begins 6–24 hours after last drink, with seizure risk peaking at 24–48 hours and delirium tremens onset at 48–96 hours; acute withdrawal resolves in 5–7 days. The 4 medically dangerous alcohol withdrawal symptoms are tremors, seizures, tachycardia, and delirium tremens. Alcohol withdrawal is life-threatening — seizures occur in 5–10% of cases, delirium tremens occurs in 3–5% of cases, and delirium tremens carries 5–15% mortality without medical treatment. See alcohol detox in Florida for detailed medical withdrawal management protocols.
• Benzodiazepines (alprazolam, clonazepam, diazepam) — short-acting benzodiazepine withdrawal begins 1–2 days after last dose. Long-acting benzodiazepine withdrawal begins 3–7 days after last dose. Duration depends on half-life and duration of use — protracted withdrawal extends weeks to months. The 4 life-threatening benzodiazepine withdrawal symptoms are anxiety, tremors, seizures, and psychosis. Benzodiazepine withdrawal is life-threatening — abrupt discontinuation produces seizures and requires medically supervised tapering at 10–25% dose reduction per week.
• Stimulants (cocaine, methamphetamine) — withdrawal begins within hours of last use, peaks at days 2–4, and resolves in 7–14 days. The 4 primary stimulant withdrawal symptoms are fatigue, hypersomnia, increased appetite, and anhedonia. Stimulant withdrawal produces no life-threatening physical withdrawal. Stimulant withdrawal produces severe depression with suicidal ideation in a subset of individuals during days 2–7.

Medical detox provides physician-directed pharmacological withdrawal management in a licensed clinical facility with 24-hour nursing coverage; social detox provides a supportive substance-free environment with monitoring but without medication-assisted withdrawal management. The appropriate detox type depends on the substance of dependence and withdrawal severity. The following are the 4 key differences between medical detox and social detox:

• Medication access — medical detox administers prescription medications including benzodiazepines, buprenorphine, clonidine, and anticonvulsants to manage withdrawal symptoms and prevent life-threatening complications. Social detox provides no prescription withdrawal management.
• Medical staffing — medical detox requires physician oversight and 24-hour RN coverage. Social detox is staffed by trained technicians and peer support specialists without prescriptive authority.
• ASAM level — medical detox operates at ASAM Level 3.7 (medically monitored intensive inpatient) or Level 4.0 (medically managed intensive inpatient). Social detox operates at ASAM Level 3.2 (clinically managed residential detoxification).
• Appropriate populations — medical detox is required for alcohol dependence, benzodiazepine dependence, severe opioid dependence, polysubstance dependence, and individuals with concurrent medical conditions. Social detox is appropriate for mild stimulant withdrawal and cannabis withdrawal in otherwise healthy individuals without prior complicated withdrawal episodes.

ASAM guidelines require medical detox for any substance withdrawal syndrome that carries seizure risk or life-threatening cardiovascular complications.

Detox medications are matched to the specific substance class producing withdrawal: buprenorphine and clonidine for opioids, benzodiazepines and thiamine for alcohol, long-acting benzodiazepine tapers for benzodiazepine dependence, and supportive agents for stimulant withdrawal. Evidence-based medication protocols reduce withdrawal severity, prevent medical complications, and improve treatment transition rates. The following are the medication protocols organized by substance class:

• Opioid detox medications — 3 FDA-approved medications address opioid withdrawal. Buprenorphine (Subutex/Suboxone): partial mu-opioid agonist that reduces withdrawal severity by 70–80%. Induction begins at COWS score 8 (moderate withdrawal) at 2–4 mg sublingual on day 1, stabilized at 8–16 mg/day. COWS is the Clinical Opiate Withdrawal Scale — an 11-item assessment tool scored 0–48. Clonidine: alpha-2 adrenergic agonist that reduces autonomic withdrawal symptoms — sweating, tachycardia, hypertension, muscle aches — dosed at 0.1–0.3 mg every 6–8 hours. Loperamide: peripherally acting anti-diarrheal at 4 mg initially, then 2 mg after each loose stool, maximum 16 mg/day. Ondansetron: anti-emetic at 4–8 mg every 8 hours for nausea and vomiting management.
• Alcohol detox medications — Benzodiazepines (chlordiazepoxide, diazepam, lorazepam): GABA-A agonists that substitute for alcohol's neurochemical effect and prevent seizures. Dose is tapered over 4–7 days based on CIWA-Ar scoring. Thiamine: 200–500 mg IV daily for 3–5 days to prevent Wernicke encephalopathy. Carbamazepine: anticonvulsant adjunct for individuals with prior withdrawal seizures.
• Benzodiazepine detox medications — gradual taper using long-acting benzodiazepines — diazepam or chlordiazepoxide — at dose reduction of 10–25% per week. Rapid benzodiazepine discontinuation produces status epilepticus. Adjunctive carbamazepine or gabapentin provides additional seizure prophylaxis during the taper.
• Stimulant detox medications — no FDA-approved medications target stimulant withdrawal specifically. Supportive care includes trazodone 50–100 mg at bedtime for insomnia, hydroxyzine for anxiety, and monitoring for suicidal ideation during days 2–7. Modafinil and bupropion show preliminary efficacy in clinical trials.

ASAM Level 3.7 is medically monitored intensive inpatient detoxification and ASAM Level 4.0 is medically managed intensive inpatient detoxification — the 2 highest-intensity detox settings in the 4-level ASAM continuum of care. Placement into Level 3.7 or 4.0 is determined by ASAM multidimensional assessment across 6 clinical dimensions. The following are the 2 ASAM detox levels and their defining criteria:

• ASAM Level 3.7 (Medically Monitored Intensive Inpatient) — provides 24-hour nursing care, daily physician contact, and standardized withdrawal management protocols. Level 3.7 is appropriate for individuals with moderate-to-severe withdrawal risk, stable medical conditions, and no need for ICU-level monitoring. CIWA-Ar scores of 10–20 for alcohol withdrawal place individuals at Level 3.7. Level 3.7 facilities are staffed by physicians, RNs, and licensed counselors.
• ASAM Level 4.0 (Medically Managed Intensive Inpatient) — provides 24-hour physician availability, continuous nursing care, and access to intensive care services. Level 4.0 is appropriate for individuals with severe withdrawal — CIWA-Ar above 20 for alcohol, COWS above 25 for opioids — unstable medical conditions including cardiac arrhythmias, hepatic failure, and seizure disorders, or polysubstance dependence requiring simultaneous management of multiple withdrawal syndromes. Level 4.0 care is delivered in hospital-based detox units.

ASAM placement is reassessed daily during the detox stay. Step-down from Level 4.0 to Level 3.7 occurs as medical acuity decreases. Step-down from Level 3.7 to PHP — Level 2.5 — or IOP — Level 2.1 — occurs upon withdrawal resolution and medical stabilization.

The risks of unsupervised drug detox are seizures, cardiac arrhythmias, severe dehydration, aspiration, and death. Unsupervised detox eliminates the medical safeguards that prevent and treat life-threatening withdrawal complications. Specific risks depend on the substance class. The following are the 4 substance-class-specific risks of unsupervised detox:

• Alcohol — unsupervised alcohol withdrawal produces seizures in 5–10% of alcohol-dependent individuals. Grand mal seizures cause falls, head injuries, and aspiration. Delirium tremens carries 5–15% mortality without medical treatment. Delirium tremens mortality exceeds 15% in individuals with concurrent medical conditions. Death from status epilepticus or cardiovascular collapse occurs without IV anticonvulsant administration.
• Benzodiazepines — abrupt benzodiazepine discontinuation causes rebound seizures, status epilepticus, and psychosis within 24–72 hours of cessation. Benzodiazepine withdrawal seizures occur unpredictably and require emergency anticonvulsant treatment. Abrupt discontinuation from therapeutic doses produces severe withdrawal — gradual taper over 4–12 weeks is the only safe approach.
• Opioids — opioid withdrawal is not directly fatal in otherwise healthy adults. The primary danger of unsupervised opioid detox is post-withdrawal overdose death. Opioid tolerance drops within 3–7 days of abstinence. A pre-detox opioid dose becomes lethal at this reduced tolerance threshold. Severe dehydration from vomiting and diarrhea causes electrolyte imbalances and cardiac arrhythmias in individuals with preexisting cardiac conditions.
• Stimulants — unsupervised stimulant withdrawal produces severe depression and suicidal ideation during days 2–7 of cocaine or methamphetamine cessation. Monitoring for suicidal risk is essential during this period. Psychosis — including paranoia and hallucinations — occurs in a subset of individuals during methamphetamine withdrawal.

All individuals with physiological substance dependence require medical evaluation before initiating detoxification. Verify insurance coverage to confirm benefits for medically supervised detox and step-down treatment.

Detox addresses only acute physiological withdrawal — it leaves the neurobiological, psychological, and environmental drivers of continued substance use untreated. NIDA classifies addiction as a chronic, relapsing brain disorder characterized by compulsive substance seeking despite harmful consequences. Detox resolves the physical dependence component. Addiction treatment addresses the behavioral and psychological components that drive relapse. The following are the 4 NIDA research findings on detox without subsequent treatment:

• Relapse rates exceed 80% within 12 months when detox is the only intervention. Neurobiological craving and environmental triggers remain unaddressed without behavioral treatment.
• Post-detox overdose risk is highest in the first 2 weeks following detox completion. Opioid and stimulant tolerance drops while psychological craving and environmental cues persist at pre-treatment intensity.
• Treatment engagement following detox reduces 12-month relapse rates to 40–60% — comparable to relapse rates for hypertension (50–70%) and asthma (50–70%) with behavioral management.
• Each additional month of behavioral treatment engagement reduces relapse probability. 90 days of continuous treatment is the minimum threshold associated with meaningful long-term outcome improvement (Simpson et al., 1999).

DCF-licensed programs provide structured behavioral treatment at the PHP, IOP, and outpatient levels following detox completion. Treatment includes individual therapy, group therapy, CBT, DBT, family therapy, and psychiatric medication management. Admissions coordinators work with detox facility staff to arrange same-week transition to structured programming upon medical stabilization. For Florida-specific licensing, statutes, and treatment-locator resources, see the Florida drug and alcohol rehab guide.

After drug detox, individuals transition to structured outpatient treatment within 24–48 hours of medical stabilization. Same-week transition from detox to structured treatment increases 90-day retention rates by 37% and is the clinical standard of care recommended by ASAM. The following are the 3 step-down levels provided following detox:

• Partial Hospitalization Program (PHP) — ASAM Level 2.5. 5–6 days per week, 5–6 hours per day. Daily programming includes individual therapy (3 sessions per week), group therapy, psychoeducation, psychiatric evaluation, and medication management. PHP is the recommended initial step-down level for individuals completing detox from opioids, alcohol, or benzodiazepines.
• Intensive Outpatient Program (IOP) — ASAM Level 2.1. 3–5 days per week, 3 hours per day. A minimum of 9 clinical hours per week. Step-down from PHP for individuals demonstrating clinical stability, engagement in recovery support systems, and development of independent coping skills.
• Outpatient Program — ASAM Level 1. 1–2 sessions per week. Continued therapeutic support during community reintegration. Medication-assisted treatment (MAT) continuation for individuals on buprenorphine or naltrexone. Individuals recovering from opiate addiction or heroin addiction receive long-term MAT maintenance at the outpatient level following detox completion.

DCF-licensed programs coordinate same-week step-down from detox to PHP or IOP. Verify insurance coverage to confirm benefits for treatment following detox completion.